Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial
SL Walsh, SD Comer, MR Lofwall, B Vince… - JAMA …, 2017 - jamanetwork.com
Importance Buprenorphine is an efficacious, widely used treatment for opioid use disorder
(OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and …
(OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and …
Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder
AF Nasser, MK Greenwald, B Vince… - Journal of clinical …, 2016 - journals.lww.com
A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit
opioids. Buprenorphine, a μ-opioid receptor partial agonist and kappa opioid receptor …
opioids. Buprenorphine, a μ-opioid receptor partial agonist and kappa opioid receptor …
[HTML][HTML] A phase 1 study investigating DX-2930 in healthy subjects
Y Chyung, B Vince, R Iarrobino, D Sexton… - Annals of Allergy …, 2014 - Elsevier
Background DX-2930 is a human monoclonal antibody inhibitor of plasma kallikrein under
investigation for long-term prophylaxis of hereditary angioedema. Objective To assess the …
investigation for long-term prophylaxis of hereditary angioedema. Objective To assess the …
[HTML][HTML] The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout
AS Steinberg, BD Vince, YJ Choi, RL Martin… - The Journal of …, 2017 - jrheum.org
Objective. Arhalofenate (ARH), in development for gout, has uricosuric and anti-flare
activities. ARH plus febuxostat (FBX) were evaluated in subjects with gout for serum uric …
activities. ARH plus febuxostat (FBX) were evaluated in subjects with gout for serum uric …
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine …
…, YG Wang, Y Lu, D Kelsh, B Vince… - Journal of …, 2018 - journals.sagepub.com
Background: This study evaluated the human abuse potential of solriamfetol (formerly JZP-
110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake …
110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake …
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder
SH Kollins, FA Lopez, BD Vince… - Journal of child and …, 2011 - liebertpub.com
Objectives: To determine whether treatment with guanfacine extended release (GXR) in
subjects with attention-deficit/hyperactivity disorder (ADHD) disrupted psychomotor …
subjects with attention-deficit/hyperactivity disorder (ADHD) disrupted psychomotor …
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal …
…, MP Ducharme, M Hu, B Vince… - Journal of …, 2020 - academic.oup.com
Background Clostridioides difficile infection is the most common cause of healthcare-
associated infections in the USA, with limited treatment options. Ibezapolstat is a novel DNA …
associated infections in the USA, with limited treatment options. Ibezapolstat is a novel DNA …
A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior
JD Jones, S Babalonis, R Marcus, B Vince… - Addiction …, 2020 - Wiley Online Library
Preclinical data indicate that selective kappa opioid receptor antagonists reduce nicotine
self‐administration and withdrawal symptoms. The aim of the current study was to determine …
self‐administration and withdrawal symptoms. The aim of the current study was to determine …
Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence
We demonstrate the use of modeling and simulation to investigate bioequivalence (BE)
concerns raised about generic warfarin products. To test the hypothesis that the loss of …
concerns raised about generic warfarin products. To test the hypothesis that the loss of …
[HTML][HTML] A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
B Vince, JM Hill, EJ Lawitz, W O'Riordan… - Journal of …, 2014 - Elsevier
Background & Aims Samatasvir is a pan-genotypic inhibitor of the hepatitis C (HCV) non-
structural protein 5A (NS5A). This study evaluated the antiviral activity, pharmacokinetics …
structural protein 5A (NS5A). This study evaluated the antiviral activity, pharmacokinetics …